

## Information for Commercial License Agreements for the Type 1 and Type 2 Diabetes Stigma Assessment Scales (DSAS-1 and DSAS-2)

### Introduction

The Type 1 Diabetes Stigma Assessment Scale (DSAS-1) and the Type 2 Diabetes Stigma Assessment Scale (DSAS-2) have been designed as self-report measures of perceived and experienced diabetes stigma, for completion by adults with type 1 diabetes and type 2 diabetes respectively. The Australian Centre for Behavioural Research in Diabetes (ACBRD) holds the copyright for the original scales and any subsequent modified or translated versions.

### *Protecting the integrity of the scales*

The integrity of the DSAS-1 and DSAS-2 is important, which is why we require you register your use of the scale(s) or, in the case of commercially funded projects, complete a user agreement. The purpose of this process is to ensure:

- you access the latest and most appropriate (in terms of language, culture) versions of the scales and scoring guidelines;
- we are able to track all the various uses of the scales and their translations, to protect the integrity of the measures, and guide development of new languages, user tools and information guidelines;
- there is no unauthorised use, alteration or translation of the questionnaire, and no breach of copyright.

It is important that any copies of the scales made for completion by study respondents are of good quality. This means:

- ensuring the font size and formatting aid ease of reading (in print and online); users are advised to keep the formatting as similar as possible to the original provided
- no alteration of instructions, item wording, response format or response options, except with the express written permission of the ACBRD.

Permission to use the DSAS-1 or DSAS-2 name will not be granted for any unauthorised modification or translation. Any analyses or publications of unauthorised versions may not use the DSAS-1 or DSAS-2 names and may be considered a violation of copyright protection.

### *Conditions of use in commercially funded projects*

The DSAS-1 and DSAS-2 are made available to researchers and industry for use in commercially funded projects by formal arrangement with the ACBRD. Commercially funded projects include those commissioned or sponsored by industry (e.g. pharmaceutical or medical device company), as well as those conducted by industry. A user agreement is necessary:

- to ensure that the latest and most appropriate version of the questionnaire is used,
- to gain access to the latest scoring guidelines, and
- to avoid breach of copyright.

Partners for better health

To use the DSAS-1 or DSAS-2 in commercially funded projects, there is a fee of AUD\$2000 (plus GST, if applicable) for each scale per use per language.

If you are planning to use the questionnaire in a commercially funded project, please complete the information request (**Appendix 1**) to enable an agreement to be drawn up.

### *Translation to other languages and cultures*

The DSAS-1 and DSAS-2 are currently available in the following languages:

- English (Australian), validated in an Australian non-clinical sample.

Use of the DSAS-1 or DSAS-2 in other cultural or linguistic groups would require appropriate adaptation.

Internationally accepted translation methodology involves forward-backward translation and reconciliation, to ensure the cultural and linguistic validity of the translation. It is a rigorous process, which may take 12-16 weeks. This can be undertaken by a reputable agency. Alternatively, academics may conduct their own cultural adaptation and linguistic validation without employing an agency, but assurances will need to be provided to the ACBRD that appropriate methodologies are being used (e.g. a protocol will need to be reviewed by ACBRD in advance, provision of a report upon completion).

In theory, if the translation process has created a questionnaire that is equivalent to the English version in meaning, and culturally appropriate for the target population, then the psychometric properties of the original questionnaire can be expected to also apply to the translation (though this would need to be confirmed through statistical analyses). All new translations:

- need to be authorised (i.e. agreed in advance) by the ACBRD;
- need to be overseen by the ACBRD, to ensure the integrity and appropriateness of the new translation;
- will remain the copyright of the ACBRD.

Where new translations are to be commissioned and funded by a commercial organisation, the per language fee is waived but consultancy services from the ACBRD will be required.

### *Consultancy services*

In addition to review of translation process, we can provide a number of services in relation to your use of the Abbreviation, including but not limited to:

- review of protocol or statistical analysis plan
- data analysis and/or interpretation
- contribution to study report, conference presentation, and/or peer-reviewed manuscripts.

Please email [info@acbrd.org.au](mailto:info@acbrd.org.au) if you would like to enquire about these services.

### *Scoring and use of the DSAS-1 and DSAS-2*

Guidelines for scoring and use of the DSAS-1 and DSAS-2 will be provided following execution of a formal agreement.

## ***Publications***

Browne JL, Ventura AD, Mosely K, Speight J. Measuring the stigma surrounding type 2 diabetes: development and validation of the Type 2 Diabetes Stigma Assessment Scale (DSAS-2). *Diabetes Care*, 2016;39(12):2141-2148.

Browne JL, Ventura AD, Mosely K, Speight J. Development and validation of the Type 1 and Type 2 Diabetes Stigma Assessment Scales. Poster presented at the 76<sup>th</sup> American Diabetes Association Scientific Sessions, 10-14 June 2016, New Orleans, USA.

## Appendix 1: Information for Commercial User Agreements

The following information is required for a draft agreement to be drawn up. Please return your completed form to [info@acbrd.org.au](mailto:info@acbrd.org.au). This document does not form an agreement or any obligation.

1. Your name:
2. Your position:
3. Your supervisor (if student):
4. Organisation (full legal name of company, institution):
5. Organisation's address:
6. Organisation's GST number:
7. Title, name and position of authorised signatory:
8. Study title:
9. Study reference number (if any):
10. Study start date (expected):
11. Study population (e.g. type of diabetes, age range):
12. Study sample size (expected):
13. How many times will each respondent complete the questionnaire?
14. How will the questionnaire(s) be administered (paper / online)?
15. How is this study to be funded?
16. Title(s) of questionnaire(s) required:
17. Language(s) required and country in which they will be used, e.g. English for UK, French for Canada:
18. Translations to be developed<sup>1</sup>:
19. Date questionnaire(s) required (if different from study start date):
20. Consultancy services required, if any (e.g. review of translation process; review of protocol or statistical analysis plan; interpretation of data; contribution to study report; manuscript preparation):

### **Your privacy matters.**

This information is intended for ACBRD use only and will be treated in confidence. You have the right to access, modify, rectify and delete any data that concern you. To exercise this right, please email [info@acbrd.org.au](mailto:info@acbrd.org.au).

---

<sup>1</sup> Please note: Development of translations will require consultancy by ACBRD, to ensure the integrity and appropriateness of the new translation.